Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab

Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), tropon...

Full description

Saved in:
Bibliographic Details
Published in:Open heart 2023
Main Authors: Woxholt, Sindre, Ueland, Thor, Aukrust, Pål, Anstensrud, Anne Kristine, Broch, Kaspar, Tøllefsen, Ingvild Maria, Ryan, Liv, Bendz, Bjørn, Hopp, Einar, Kløw, Nils-Einar, Seljeflot, Ingebjørg, Halvorsen, Bente, Dahl, Tuva Børresdatter, Huse, Camilla, Andersen, Geir Øystein, Gullestad, Lars, Wiseth, Rune, Amundsen, Brage H, Damås, Jan Kristian, Kleveland, Ola
Format: Article
Language:Norwegian
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with neutrophils, C-reactive protein (CRP), troponin T, MSI and infarct size. Methods STEMI patients were randomised to receive a single dose of 280 mg tocilizumab (n=101) or placebo (n=98) before percutaneous coronary intervention. Blood samples were collected before infusion of tocilizumab or placebo at baseline, during follow-up at 24–36, 72–168 hours, 3 and 6 months. 27 cytokines were analysed using a multiplex cytokine assay. Cardiac MRI was performed during hospitalisation and 6 months. Results Repeated measures analysis of variance showed significant (p
ISSN:2053-3624
2053-3624